SCHEMBL31667575

SCHEMBL31667575

COc1ccc(CN2C(=O)c3ccccc3C2Cc2ncccc2Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
HKDC1 Q2TB90 1/20 0.54
MAPT P10636 5/20 0.45
ALDH1A1 P00352 4/20 0.45
ALOX15 P16050 3/20 0.45
HSD17B10 Q99714 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.44
SCN9A Q15858 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CASP3 P42574 1/20 0.41
APP P05067 2/20 0.40
SNCA P37840 2/20 0.40
BRD4 O60885 1/20 0.40
FFAR1 O14842 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31667048 0.87 KDM4E (0.40) KDM4EHKDC1MAPTALDH1A1HSD17B10
SCHEMBL31667574 0.87 KDM4E (0.40) KDM4EHKDC1MAPTALDH1A1ALOX15
SCHEMBL31667164 0.87 MAPT (0.40) KDM4EHKDC1MAPTALDH1A1SMN1; SMN2
SCHEMBL31667285 0.85 KDM4E (0.43) KDM4EHKDC1MAPTALDH1A1ALOX15
SCHEMBL31667641 0.83 KDM4E (0.43) KDM4EHKDC1MAPTALDH1A1ALOX15
SCHEMBL31666998 0.82 HPGD (0.36) KDM4EHKDC1MAPTALDH1A1MAPK1
SCHEMBL31667711 0.82 ALDH1A1 (0.37) KDM4EHKDC1MAPTALDH1A1SMN1; SMN2
SCHEMBL31667547 0.81 PRMT5 (0.38) KDM4EHKDC1MAPTALDH1A1ALOX15
SCHEMBL31667014 0.80 PRMT5 (0.38) MAPTALDH1A1ALOX15MAPK1TSHR
SCHEMBL31667124 0.79 ALDH1A1 (0.35) KDM4EMAPTALDH1A1SMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 KDM4E 3382/4885HKDC1 1441/4885MAPT 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.